2024 ISV ANNUAL CONGRESS
SEOUL, SOUTH KOREA
Dragon City Hotel
21 – 23 October 2024
Dear ISV Members, Colleagues, and Friends,
We are thrilled to announce that the International Society for Vaccines (ISV) Annual Congress returns to Asia, October 21-23, 2024 at the Dragon City Hotel, Seoul, Korea. The International Vaccine Institute (IVI), established by the United Nations Development Programme is partnering with ISV for this important event.
The 2024 ISV Annual Congress welcomes vaccinologists from all disciplines of human and veterinary prophylactic and therapeutic vaccination and immunotherapy. Participants come from every discipline, including basic research, development, regulatory issues, manufacturing, and epidemiology and from all sectors, whether academic, industrial, governmental or non-governmental institutions.
2024 Congress Chairs
Joon Haeng Rhee
Chonnam National University Medical School, South Korea
Margaret Liu
ProTherImmune, USA
Karolinska Institutet, Sweden
Shan Lu
UMASS Chan Medical School, USA
Ken Ishii
University of Tokyo, Japan
Jerome Kim
IVI – South Korea
Invited Speakers
(more to be added)
Peter Lawaetz Andersen
Novo Nordisk Foundation, Denmark
James Baber
Pfizer Vaccine Research and Development, Australia
Alejandra Capozzo
UAI, Argentina
Danilo Casimiro
Sanofi, USA
Corey Casper
AAHI, USA
Nam-Hyuk Cho
Seoul National University, South Korea
Seung Ho Choo
CREO SG Vaccine Institute, South Korea
Mark Connors
NIAID, HIV-Specific Immunity Section, USA
Simon Draper
University of Oxford, United Kingdom
Sarah Gilbert
University of Oxford, United Kingdom
Cyril Guyard
BIOASTER, France
Brittany L. Hartwell
University of Minnesota, USA
SungHee Hong
SK bioscience Co., Ltd., South Korea
Joseph Jardine
Scripps Research Institute, USA
Hong Jin
Blue Lake Biotechnology, USA
Jerome Kim
International Vaccine Institute (IVI), South Korea
Shee-Eun Lee
Chonnam National University, South Korea
Guanghui Ma
Chinese Academy of Sciences, China
Leyuan Ma
University of Pennsylvania, USA
Andreas Holm Mattsson
Evaxion, Denmark
Dal-Hee Min
Lemonex/SNU, South Korea
Moon Nahm
University of Alabama at Birmingham, USA
Nicaise Ndembi
Africa Centres for Disease Control and Prevention (Africa CDC), Ethiopia
Albert Osterhaus
University of Veterinary Medicine Hannover (TiHo), Germany
Sallie Permar
Cornell University, USA
Angie Rasmussen
University of Saskatchewan, Canada
Nina Russell
Bill & Melinda Gates Foundation, USA
Yoshimasa Takahashi
National Institute of Infectious Diseases, Japan
Axel Timmermann
Pusan University, South Korea
Birgit Weinberger
University of Innsbruck, Austria
Tao Zhu
CanSino Biologics, China
2024 Scientific Committee
– CO-CHAIRS-
David Weiner, The Wistar Institute – USA
Alexander Bukreyev, University of Texas Medical Branch – USA
Kimberly Matheson, Sanofi Canada – Canada
Pervin Anklesaria, Bill & Melinda Gates Foundation – USA
Jason McLellan, University of Texas, Austin – USA
Neil Almond, MHRA – UK
Jacqueline Miller, Moderna – USA
Annaliesa Anderson, Pfizer – USA
Peter Openshaw, Imperial College – London
Danilo Casimiro, Aeras – USA
Clarisa, Palatnik de Sousa, Federal University of Rio de Janeiro – Brazil
Hualan Chen, National Avian Influenza Reference Laboratory – China
Sanjay Phogat, GSK – Italy
Zhiwei Chen, Hong Kong University – China
Punnee Pitisuttithum, Mahidol University-Thailand
Andrew Pollard, Oxford Vaccine Group – UK
Mark Connors, NIH – USA
Gi-eun Rhie, Vaccine Research Center KDCA/KNIH – South Korea
David Salisbury, UK Department of Health (and WHO) – UK
Maria Elena Botazzi, Baylor – USA
Ann Ginsberg, Bill & Melinda Gates Foundation – USA
Manki Song, IVI – South Korea
Hoon Kim, SK bioscience – South Korea
Frederic Tangy, Institut Pasteur – France
Baik Lin Seong, University – South Korea
Petro Terblanche, Afrigen Biologics & Vaccines – South Africa
Anna Lise, Williamson, University of Cape Town – South Africa
Karin Loré, Karolinska Institutet – Sweden
Kapil Maithal, Vaccine Technology Centre – India
ISV Annual Supporters
